News Feed Opinion Career Insight Dialogues Blog Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
July, 2024
July 2024
M T W T F S S
1234567
891011121314
15161718192021
22232425262728
293031  
Discuss the future of immuno-oncology with Agenus at ESMOGI24
Photo from Agenus/LinkedIn
Jun 27, 2024, 12:44

Discuss the future of immuno-oncology with Agenus at ESMOGI24

Agenus shared on LinkedIn:

“If you are a physician attending ESMOGI24 in Munich from June 26-29, our Medical Affairs team would welcome the opportunity to discuss the future of immuno-oncology with you.

Schedule a meeting here.”

Source: Agenus/LinkedIn

Agenus cancer ESMOGI24 immuno-oncology Munich OncoDaily Oncology
Career
Jul 2, 2024, 01:43
Christian Rolfo joins James Cancer Hospital & Solove Research Institute team as director of our Division of Medical Oncology
Blog
Jul 2, 2024, 01:33
National Cancer Institute - Warren Kibbe is the new deputy director for data science and strategy
Insight
Jul 1, 2024, 23:51
Piotr Wysocki: Neoadjuvant therapy for renal-cell cancer patients is still in its infancy, unlike in melanoma
Blog
Jul 1, 2024, 19:36
Monica Bertagnolli: Molecular Portrait of Key Driver of pancreatic cancer
Insight
Jul 1, 2024, 19:24
Léa Ikhlef: The use of extracellular vesicles as a communication tool by TAMS in CLL
Insight
Jul 1, 2024, 19:16
Susanna Greer: This researcher is making tools to improve quality of life
Blog
Jul 1, 2024, 19:04
Julie S. Torode: Ethiopia‘s first ever breast cancer guideline
Blog
Jul 1, 2024, 18:48
Yüksel Ürün: Empowering Cancer Survivors with Employment Support!
Insight
Jul 1, 2024, 18:24
Paolo Tarantino: How long should adjuvant T-DM1 be given for stage I HER2+ eBC?
Blog
Jul 1, 2024, 18:12
Two great minds teaming up to fight cancer - Saint John’s Cancer Institute
Blog
Jul 1, 2024, 18:02
Kai-Cheng Hsu: 25 Years of Innovation and Excellence in Biomedical Technology!
Blog
Jul 1, 2024, 17:38
Sara Elena Rebuzzi: Study protocol of the ongoing study on the first-line therapy in mRCC patients